- Email: [email protected]
Targeted Therapies for the Treatment of Lung Cancer-Continuing Medical Education Information
Targeted Therapies for the Treatment of Lung Cancer Continuing Medical Education Information Date of Original Release: 12/31/05 Date of Expiration: 12/31/06 Medium Used: Educational activity in the form of a printed enduring material Statement of Need Our expanding knowledge of the signaling pathways that participate in the growth and metastasis of lung cancer have identified many opportunities for therapeutic intervention, and several candidate drugs are under investigation. Efforts are under way to determine the optimal settings, patient populations, and combinations in which to employ these targeted agents. Individual therapeutic agents targeting specific signaling pathways have led to inhibition of tumor growth and metastasis in lung cancer. However, the potential exists for individual tumor cells to be refractory to such agents, by means of mutations or other mechanisms, resulting in reduced efficacy. It is hoped that, by targeting multiple pathways through combining targeted agents, even greater efficacy and survival can be achieved. This journal supplement will highlight novel targeted regimens currently being developed for the treatment of lung cancer as presented at the 2005 Targeted Therapies for the Treatment Lung Cancer Conference. Target Audience The target audience for this activity includes oncologists involved in the care and treatment of patients with non–small cell lung cancer (NSCLC). Educational Purpose The educational purpose of this activity is to provide oncologists with information on recent advances in the use of targeted agents in the treatment of lung cancer. Educational Objectives After reading this journal supplement, participants should be able to: 1. Assess the efficacy and safety of epidermal growth factor receptor (EGFR)–targeted agents in the treatment of NSCLC. 2. Relate the mechanism of both available and developing vascular endothelial growth factor (VEGF) inhibitors, and evaluate recent clinical data on the use of such inhibitors in the treatment of cancer. 3. Discuss the rationale for combination regimens targeting both the EGFR and VEGF signaling pathways as a means of cancer therapy. 4. Evaluate recent clinical data regarding the efficacy of EGFR-targeted agents in specific patient subpopulations. Method of Participation This journal supplement will be utilized to engage readers and enhance the learning process.
Accreditation Statement The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation of Credit The CBCE designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. CME Certificate Participants who submit a Participant Information Form and Evaluation Form will receive their CME certificate 4 weeks after the activity. Acknowledgement of Commercial Support The CBCE gratefully acknowledges the educational grant provided by Genentech BioOncology and OSI Oncology. Disclosure of Unlabeled Uses This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference. Disclaimer The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or the commercial supporter(s) Genentech BioOncology and OSI Oncology. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to appraise the information presented critically, and are encouraged to consult the above-mentioned resources as well as available literature on any product or device mentioned in this program. Faculty Disclosures Full faculty disclosures can be found on pages xx–xx. Institutional Disclosure The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter(s) of this activity as well as the manufacturer(s) of certain drugs and/or devices discussed in this activity. Disclosure of Potential Conflicts of Interest The CBCE assesses conflicts of interest with its faculty, planners, and managers of CME activities. Identified conflicts of interest are thoroughly evaluated by the CME Planning Committee for fair balance, scientific objectivity relative to studies utilized in this activity, and patient care recommendations. The CBCE is committed to providing its learners with high-quality, unbiased, and state-of-the-art education.
The following faculty have reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process: Name of Faculty or Presenter Philip D. Bonomi, MD Paul A. Bunn, Jr, MD Martin J. Edelman, MD Corey J. Langer, MD Ronald B. Natale, MD Alan B. Sandler, MD
Reported Area(s) of Conflict Speaker program, consultant, and investigator for Genentech, Inc.; consultant and investigator for OSI Oncology. Consultant for Genentech, Inc., and OSI Oncology Receipt of honoraria and a consultant for Genentech, Inc. Consultant and research support for Genentech, Inc., and OSI Oncology. Grant/research support from Genentech, Inc. Receipt of honoraria and a consultant for Genentech, Inc.
The following planners and managers have reported real or apparent conflicts of interest: Name of Planner or Manager Reported Area(s) of Conflict Roy S. Herbst, MD, PhD Speaker program, consultant, and investigator for Genentech, Inc. In addition, the CBCE reports the following relationships with commercial interests associated with this activity: Name of Commercial Interest Genentech BioOncology and OSI Oncology
Type of Financial Relationship Educational grant
CME Inquiries For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: [email protected].
Accreditation Statement The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation of Credit The CBCE designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. CME Certificate Participants who submit a Participant Information Form and Evaluation Form will receive their CME certificate 4 weeks after the activity. Acknowledgement of Commercial Support The CBCE gratefully acknowledges the educational grant provided by Genentech BioOncology and OSI Oncology. Disclosure of Unlabeled Uses This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference. Disclaimer The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or the commercial supporter(s) Genentech BioOncology and OSI Oncology. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to appraise the information presented critically, and are encouraged to consult the above-mentioned resources as well as available literature on any product or device mentioned in this program. Faculty Disclosures Full faculty disclosures can be found on pages xx–xx. Institutional Disclosure The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter(s) of this activity as well as the manufacturer(s) of certain drugs and/or devices discussed in this activity. Disclosure of Potential Conflicts of Interest The CBCE assesses conflicts of interest with its faculty, planners, and managers of CME activities. Identified conflicts of interest are thoroughly evaluated by the CME Planning Committee for fair balance, scientific objectivity relative to studies utilized in this activity, and patient care recommendations. The CBCE is committed to providing its learners with high-quality, unbiased, and state-of-the-art education.
The following faculty have reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process: Name of Faculty or Presenter Philip D. Bonomi, MD Paul A. Bunn, Jr, MD Martin J. Edelman, MD Corey J. Langer, MD Ronald B. Natale, MD Alan B. Sandler, MD
Reported Area(s) of Conflict Speaker program, consultant, and investigator for Genentech, Inc.; consultant and investigator for OSI Oncology. Consultant for Genentech, Inc., and OSI Oncology Receipt of honoraria and a consultant for Genentech, Inc. Consultant and research support for Genentech, Inc., and OSI Oncology. Grant/research support from Genentech, Inc. Receipt of honoraria and a consultant for Genentech, Inc.
The following planners and managers have reported real or apparent conflicts of interest: Name of Planner or Manager Reported Area(s) of Conflict Roy S. Herbst, MD, PhD Speaker program, consultant, and investigator for Genentech, Inc. In addition, the CBCE reports the following relationships with commercial interests associated with this activity: Name of Commercial Interest Genentech BioOncology and OSI Oncology
Type of Financial Relationship Educational grant
CME Inquiries For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: [email protected].